First EU-GMP Certification Obtained by Aurora Cannabis

Image | adobe.stock/aiisha

In a recent press release, Aurora Cannabis Inc., a global medical cannabis company based in Canada, unveiled that the company’s Brampton, Ontario, dedicated distribution center had obtained a European Union Good Manufacturing Practice (EU-GMP) certification (1). With the certification, Aurora Cannabis Inc. is able to grow their “international export capabilities.”

“Securing EU-GMP certification at manufacturing and distribution facilities within our network is an important validation of our differentiated approach to operating as a global medical cannabis company,” said Jill Lau, Vice President of Canadian Operations at Aurora, in the press release (1). “By adding certification for our distribution center, we are now uniquely positioned to ensure patients worldwide have consistent access to superior quality medical cannabis from the largest Canadian exporter.”

To receive an EU-GMP certification, production facilities need to meet EudraLex “Rules Governing Medicinal Products in the European Union” requirements, as well as “demonstrate a high degree of quality and consistency in their manufacturing procedures, a requirement for the export of medical cannabis products into Europe,” (1). Through receipt of the certification, Aurora Cannabis’s distribution center, the facility can be used internationally for receiving, distributing, and storage of materials and finished products.

In January 2025, Aurora Cannabis Inc, announced it had partnered with the Erfurt University of Applied Sciences in Leuna, Germany to create a six-month student internship program in medical cannabis cultivation (2). Students taking the Horticultural Crop Production course will gain experience in cloning, care, harvesting, packaging and cleaning, as well as join in research and development projects. The six-month program is taking place at Aurora's EU-GMP facility in Leuna, considered one of the only sites in Germany permitted to grow medical cannabis.

Aside from their moves in the EU, Aurora Cannabis Inc. disclosed in a February 2025 press release (3), that the company had removed the requirement for patients to acquire concession cards in order to access its IndiMed brand products. As a result from this decision, any medical cannabis patients in Australia can be prescribed IndiMed products. The change, made in conjunction with its subsidiary MedReleaf Australia, now allows for more access for medical cannabis products for patients in the country.

References

1. Aurora Cannabis Inc. Aurora completes first-ever EU-GMP certification for the company’s dedicated Distribution Centre https://www.prnewswire.com/news-releases/aurora-completes-first-ever-eu-gmp-certification-for-the-companys-dedicated-distribution-centre-302503683.html (accessed Jul 18, 2025).
2. McEvoy, E. Aurora cannabis announces cultivation internship program in Germany https://www.cannabissciencetech.com/view/aurora-cannabis-announces-cultivation-internship-program-in-germany (accessed Jul 18, 2025).
3. McEvoy, E. Aurora Cannabis Inc. removes concession card requirements for patients https://www.cannabissciencetech.com/view/aurora-cannabis-inc-removes-concession-card-requirements-for-patients (accessed Jul 18, 2025).